Summary
In the EU, well over 8 million people have been found to drive under the influence of illicit drugs. In the US, fatal traffic accidents caused by drugged driving has already surpassed alcohol-induced traffic deaths. Drug intoxication testing is an efficient mechanism that helps to avoid drug related fatalities, such as traffic accidents or heavy machinery mishandling. However, the current testing solutions are not suited for wide scale deployment and thus cannot make a meaningful impact in the war against drugs. They are hampered by the bulkiness and high cost of instrumentation, uncertain levels of accuracy, and inability to detect the growing variety of drugs.
BioMensio multi-drug testing platform is the first palm-sized and highly accurate device to detect drug intoxication from saliva, designed specifically for the police to detect drugged drivers, paramedics to better understand patient condition, and employers to prevent workplace injuries. Our patented bio-sensing technology enables to simultaneously measure a person’s intoxication from virtually any widely used narcotics, in an easy-to-administrate test that provides results in just 1-2 minutes. This by far exceeds the performance of
any other current or up-and-coming technology.
BioMensio is a spin-off company from Siemens Technology Accelerator and VTT Technical Research Centre of Finland, and has been backed with €3.5 million early stage funding. We are now beyond the proof-of-concept phase and are ready to scale our technology. We target the globally growing €1 billion saliva-based rapid drug testing market, which is fuelled by increasingly stringent government norms and workplace drug testing legalisation worldwide. As the key to reduce drug related fatalities and injuries is widely deploying and applying preventative tools, the main goal of our project is bring our patented bio-sensing platform to the mass market.
BioMensio multi-drug testing platform is the first palm-sized and highly accurate device to detect drug intoxication from saliva, designed specifically for the police to detect drugged drivers, paramedics to better understand patient condition, and employers to prevent workplace injuries. Our patented bio-sensing technology enables to simultaneously measure a person’s intoxication from virtually any widely used narcotics, in an easy-to-administrate test that provides results in just 1-2 minutes. This by far exceeds the performance of
any other current or up-and-coming technology.
BioMensio is a spin-off company from Siemens Technology Accelerator and VTT Technical Research Centre of Finland, and has been backed with €3.5 million early stage funding. We are now beyond the proof-of-concept phase and are ready to scale our technology. We target the globally growing €1 billion saliva-based rapid drug testing market, which is fuelled by increasingly stringent government norms and workplace drug testing legalisation worldwide. As the key to reduce drug related fatalities and injuries is widely deploying and applying preventative tools, the main goal of our project is bring our patented bio-sensing platform to the mass market.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/848986 |
| Start date: | 01-03-2019 |
| End date: | 31-03-2022 |
| Total budget - Public funding: | 4 060 405,00 Euro - 2 492 021,00 Euro |
Cordis data
Original description
In the EU, well over 8 million people have been found to drive under the influence of illicit drugs. In the US, fatal traffic accidents caused by drugged driving has already surpassed alcohol-induced traffic deaths. Drug intoxication testing is an efficient mechanism that helps to avoid drug related fatalities, such as traffic accidents or heavy machinery mishandling. However, the current testing solutions are not suited for wide scale deployment and thus cannot make a meaningful impact in the war against drugs. They are hampered by the bulkiness and high cost of instrumentation, uncertain levels of accuracy, and inability to detect the growing variety of drugs.BioMensio multi-drug testing platform is the first palm-sized and highly accurate device to detect drug intoxication from saliva, designed specifically for the police to detect drugged drivers, paramedics to better understand patient condition, and employers to prevent workplace injuries. Our patented bio-sensing technology enables to simultaneously measure a person’s intoxication from virtually any widely used narcotics, in an easy-to-administrate test that provides results in just 1-2 minutes. This by far exceeds the performance of
any other current or up-and-coming technology.
BioMensio is a spin-off company from Siemens Technology Accelerator and VTT Technical Research Centre of Finland, and has been backed with €3.5 million early stage funding. We are now beyond the proof-of-concept phase and are ready to scale our technology. We target the globally growing €1 billion saliva-based rapid drug testing market, which is fuelled by increasingly stringent government norms and workplace drug testing legalisation worldwide. As the key to reduce drug related fatalities and injuries is widely deploying and applying preventative tools, the main goal of our project is bring our patented bio-sensing platform to the mass market.
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
